Skin and salivary gland malignancies
High daily opioid use (defined as 30 mg oral morphine equivalent dose or higher) for more than 7 days at time of enrollment
Concurrent second active malignancy
Pregnant or lactating women
Psychological disorder requiring pharmacologic treatment
Regular systemic steroid use
Regular anticonvulsant, neuropathic or antidepressant use
Renal Impairment
Defined as creatinine clearance < 60 mL/min
Liver Dysfunction
Defined as total bilirubin > 34.2 μmol/L
Documented true allergy or contraindications to Acetaminophen, NSAIDs, Pregabalin, pantoprazole or opioids
History of upper gastrointestinal bleed
Known bleeding disorder
History of or current substance use disorder
Copyright and License information: The Author(s) ©2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.
Ask a
question
Post a Question
